Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults

Gut

Volumn 52, Issue SUPPL. 3, 2003, Pages

  Ryder, S D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; DIETHYLSTILBESTROL; DOXORUBICIN; FLUTAMIDE; INTERFERON; OCTREOTIDE; RETINOID; TAMOXIFEN;

ADOPTIVE IMMUNOTHERAPY; ANGIOGRAPHY; ARTIFICIAL EMBOLISM; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INJECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PERCUTANEOUS DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY RADIATION; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 0037407560     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.suppl_3.iii1     Document Type: Review

References (145)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
2. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cell cancer in the UK, 1979-1994. Lancet 1997;350:1142-3.
3. Okuda K, Fujimoto I, Hanai A, et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-72.
4. Okuda K. Clinical presentation and natural history of hepatocellular carcinoma and other liver cancers. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997:1-12.
5. Bosch FX, Munoz N. Hepatocellular carcinoma in the world: epidemiological questions. In: Tabor E, Di Bisceglie AM, Purcell RH , eds. Etiology, Pathology and Treatment of Hepatocellular Carcinoma. The Woodlands, Texas: Portfolio, 1991.
6. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;86:1143-50.
7. Lee HS, Han CJ, Kim CY. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B endemic area. Cancer 1993;72:2564-7.
8. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998;28:751-5.
9. Grando-Lemaire V, Guettier C, Chevret S, et al. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:508-13.
10. Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumour of adolescents and young adults with distinct clinicopathological features. Cancer 1980;46:372-9.
11. Okuda K, Nakashima T, Sakamoto K. Hepatocellular carcinoma arising in noncirrhotic and highly cirrhotic livers: a comparative study of histopathology and frequency of hepatitis B markers. Cancer 1982;49:450-5.
12. Chen DS, Hoyer BH, Nelson J. Detection and properties of hepatitis B viral DNA in liver tissues from patients with hepatocellular carcinoma. Hepatology 1982;2:42-6S.
13. De Mitri MS, Puossin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-15.
14. Goh J, Callagy G, McEntee G, et al. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. Eur J Gastroenterol Hepatol 1999;11:915-19.
15. Sakuma K, Saito N, Kasai M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988;8:1642-6.
16. Tsukuma H, Hiyami T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
17. Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999;81:695-9.
18. Shiratori Y, Shiina S, Imamura M. Characteristic difference of hepatocellular carcinoma between hepatitis B and C-viral infection in Japan. Hepatology 1995;22:1027-33.
19. Faivre J, Forman D, Esteve J, et al. Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group. Eur J Cancer 1998;34:1103-9.
20. Yang Q, McDonnell SM, Khoury MJ, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-53.
21. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
22. Ryder SD, Koskinas J, Rizzi PM, et al. Hepatocellular carinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology 1995;22:718-22.
23. Lee F. Cirrhosis and hepatoma in alcoholics. Gut 1996;7:77-85.
24. Miyakawa H, Izumi N, Marumo F, et al. Roles of alcohol hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996;20:91-4A.
25. Loof L, Adami HO, Sparen P, et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. Hepatology 1994;20:101-4.
26. Howel D, Metcalf JV, Gray J, et al. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 1999;45:756-60.
27. Polio J, Enriquez RE, Chow A, et al. Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J Clin Gastroenterol 1989;11:220-4.
28. Sheu JC, Sung JL, Chen DS. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-66.
29. Barbara L, Benzi G, Galani S. Natural history of small untreated hepatocellular carcinoma in cirrhosis; a multivariate analysis of prognostic factors of tumour growth rate and patient survival. Hepatology 1992;16:132-7.
30. Cottone M, Viridone R, Fusco G, et al. Asymptomatic HCC in Childs A cirrhosis. Gastroenterology 1989;96:1566-71.
31. Columbo M, Sangiovanni A. The natural history of hepatocellular carcinoma. Ital J Gastroenterol 1992;24:95-9.
32. Okazaki N, Yoshino M, Yoshida T, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumour volume doubling time. Cancer 1989;63:2207-10.
33. Alpert E. Human alpha-1 fetoprotein. In: Okuda K, Peters RL, eds. Hepatocellular Carcinoma. New York: Wiley, 1976:353-67.
34. Taketa K, Endo Y, Sekiya C. A collaborative study for the evaluation of lectin- reactive alpfa-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
35. Leibman HA, Furie BC, Tong MJ. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
36. Lok ASF, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110-15.
37. Columbo M, de Franchis R, Del Ninnno E. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80.
38. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38.
39. Oka H, Kuriola N, Kim K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12:680-7.
40. Mima S, Sekiya C, Kanagawa H. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994;9:361-5.
41. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae. Prospective study of 1400 hepatitis B surface antigen positive Alaskan native carriers. Arch Int Med 1990;150:1051-4.
42. Sherman M, Peltkian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
43. Liaw Y-F, Tai D-I, Chu C-M, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. Gastroenterology 1986;90:263-6.
44. Tanake S, Kitamura T, Nakanishi K, et al. Effectiveness of periodic checkup by ultrasonography for the early diagnosis of hepatocellular carcinoma. Cancer 1990;66:2210-14.
45. Sheu J-C, Sung J-L, Chen D-S, et al. Early detection of hepatocellular carcinoma by real time ultrasonography. A prospective study. Cancer 1985;56:660-6.
46. Solmi L, Primerano AMM, Gandolfi L. Ultrasound follow-up of patients at risk of hepatocellular carcinoma: results of a prospective study in 360 cases. Am J Gastroenterol 1996;91:1189-93.
47. Frazer C. Imaging of hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:750-6.
48. Kanematsu T, Sonoda T, Takenaka K, et al. The value of ultrasound in the diagnosis and treatment of small hepatocellular carcinoma. Br J Surg 1985;72:23-5.
49. Bartolozzi C, Lencioni R, Caramella D, et al. Small hepatocellular carcinoma. Detection with US, CT, MR imaging, DSA, and Lipiodol-CT. Acta Radiol 1996;37:69-74.
50. Saada J, Bhattacharya S, Dhillon AP, et al. Detection of small hepatocellular carcinomas in cirrhotic livers using iodised oil computed tomography. Gut 1997;41:404-7.
51. Bizollon T, Rode A, Bancel B, et al. Diagnostic value and tolerance of lipiodol- computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol 1998;28:491-6.
52. Horigome H, Nomura T, Saso K, et al. Limitations of imaging diagnosis for small hepatocellular carcinoma: comparison with histological findings. J Gastroenterol Hepatol 1999;14:559-65.
53. Das DK. Cytodiagnosis of hepatocellular carcinoma in fine-needle aspirates of the liver: its differentiation from reactive hepatocytes and metastatic adenocarcinoma. Diagn Cytopathol 1999;21:370-7.
54. Huang GT, Sheu JC, Yang PM, et al. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma-a study based on 420 patients. J Hepatol 1996;25:334-8.
55. Rizzi PM, Kane PA, Ryder SD, et al. Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. Gastroenterology 1994;107:1425-9.
56. Achkar JP, Araya V, Baron RL, et al. Undetected hepatocellular carcinoma: clinical features and outcome after liver transplantation. Liver Transpl Surg 1998;4:477-82.
57. Kanematsu M, Hoshi H, Yamada T, et al. Small hepatic nodules in cirrhosis: ultrasonographic, CT, and MR imaging findings. Abdom Imaging 1999;24:47-55.
58. Tang Y, Yamashita Y, Arakawa A, et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol 1999;172:1547-54.
59. O'Grady JG, Polson RJ, Rolles K, et al. Liver transplantation for malignant disease: results in 93 consecutive patients. Ann Surg 1988;207:373-9.
60. Iwatsuki S, Starzl TE, Sheahan DC, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221-9.
61. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-51.
62. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;14:728-9S.
63. McPeake JR, O'Grady JG, Zaman S, et al. Liver transplantation for primary hepatocellular carcinoma: tumour size and number determine outcome. J Hepatol 1993;18:226-34.
64. Lovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumour-node metastasis classification does not have prognostic power. Hepatology 1998;27:1572-7.
65. Ringe B, Pichlmayer R, Witelkind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270-85.
66. Tan KC, Rela M, Ryder S, et al. Experience of orhotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8cm in patients with cirrhosis. Br J Surg 1995;82:253-6.
67. Michel J, Suc B, Fourtainier G, et al. Recurrence of hepatocellular carcinoma in cirrotic patients after liver resection or transplantation. Transplant Proc 1995;27:1799-800.
68. Otto G, Heuschen U, Hoffman WJ, et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma. Ann Surg 1998;227:424-32.
69. Llovet JM, Fuster J, Bruix J. Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
70. Lai E, Fan S-T, Chu K-M, et al. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 1995;221:291-8.
71. Franco D, Capussotti L, Smadja C, et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 1990;98:733-8.
72. Kanematsu T, Takenada K, Matsumata T, et al. Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer. Ann Sur 1984;199:51-6.
73. Fan S-T, Lo C-M, Lai E, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331:1547-52.
74. Ouchi K, Matsubara S, Fukahara K, et al. Recurrence of hepatocellular carcinoma in the liver remnant after hepatic resection. Am J Surg 1993;166:270-3.
75. Adachi E, Maneda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-75.
76. Gouillat C, Manganas D, Berard P. Ultrasonically guided hepatic tumourectomy. J Am Coll Surg 1995;180:617-18.
77. Wood WJ, Rawlings M, Evans H, et al. Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. Am J Surg 1988;155:663-6.
78. Soreide O, Czemiak A, Bradpiece H, et al. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg 1986;151:518-23.
79. Nagorney DM, Adson MA, Weiland LH, et al. Fibrolamellar hepatoma. Am J Surg 1985;149:113-19.
80. Vauthey J-N, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after surgical resection for hepatocellular carcinoma. Am J Surg 1995;169:28-35.
81. Ringe B, Wittekind C, Weinmann A, et al. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 1992;175:299-305.
82. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997;26:877-83.
83. Iwatsuki S, Starzl TE. Personal experience with 411 hepatic resections. Ann Surg 1988;208:421-34.
84. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 1999;5:91-5.
85. Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992;69:925-9.
86. Lin SM, Lin DY, Lin CJ. Percutaneous ethanol injection therapy in 47 cirrhotic patients with hepatocellular carcinoma 5 cm or less: a long-term result. Int J Clin Pract 1999;53:257-62.
87. Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997;7:514-19.
88. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.
89. Vilana R, Bruix J, Bru C, et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
90. Shibata T, Kojima N, Tabuchi T, et al. Transthoracic percutaneous ethanol injection therapy for hepatocellular carcinomas located beneath the diaphragm. J Vasc Interv Radiol 1998;9:97-100.
91. Ishii H, Okada S, Okusaka T, et al. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1998;82:1638-42.
92. Di Stasi M, Buscarini L, Livraghi T, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 1997;32:1168-73.
93. Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995;22:522-6.
94. Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121-6.
95. Ohnishi K. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatogastroenterology 1998;45 (suppl 3):1254-8.
96. Ohnishi K, Yoshioka H, Ito S, et al. Prospective randomized controlled trial comparing percutaneous acetic acid injection ond percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27:67-72.
97. Ohmoto K, Yamamoto S. Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma on the liver surface. Am J Gastroenterol 2000;95:2401-3.
98. Francica G, Marone G. Ultrasound-guided percutaneous treatment of hepatocellular carcinoma byradiofrequency hyperthermia with a 'cooled-tip needle'. A preliminary clinical experience. Eur J Ultrasound 1999;9:145-53.
99. Allgaier HP, Deibert P, Zuber I, et al. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999;353:1676-7.
100. Morris DE, Abouljoud M. Short-term results of radiofrequency ablation in liver tumors. Am J Surg 2000;179:527.
101. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381-91.
102. Livraghi T, Goldberg SN Lazzaroni S, et al. Hepatocellular carcinoma: radio- frequency ablation of medium and large lesions. Radiology 2000;214:761-8.
103. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-61.
104. Dyon D, Mouzon A, Jourde AN, et al. L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol 1974;17:593-603.
105. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolisation therapy for hepatoma using ethodized oil, cisplatin, and gelatin sponge. Cancer 1987;60:1194-203.
106. Ryder SD, Rizzi PM, Metivier E, et al. Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut 1996;38:125-8.
107. Okazaki M, Higashihara H, Koganemaru F, et al. Intraperitoneal haemorrhage from hepatocellular carcinoma: emergency chemoembolisation or embolization. Radiology 1991;180:647-51.
108. Shibata J, Fujiyama S, Sato T, et al. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989;64:1586-94.
109. Lin DY, Liaw YF, Lee TY, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology 1988;94:453-6.
110. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-34.
111. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomised controlled trial in a single institution. Hepatology 1998;27:1578-83.
112. Madden MV, Krige JEJ, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-600.
113. Pelletier G Roche A, Ink O, et al. A randomised trial of hepatic arterial chemoembolisation in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
114. Group d'Etude et de Traitment de Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
115. Llovet JM, Real MI, Montana X, et al. Aterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
116. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
117. Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatacellular carcinoma by transcatheter arterial embolization cambined with intrarterial infusion of a mixture of cisplatin and ethodised oil. Gastroenterology 1989;97:965-71.
118. Kuroda C, Iwasaki M, Tanaka T, et al. Gallbladder infarction following hepatic transcatheter arterial embolisation: angiagraphic study. Radiology 1983;149:85-9.
119. Lencioni R, Vignali C, Caramella D, et al. Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 1994;17:70-5.
120. Yamamoto K, Masuzawa M, Kato M, et al. Evaluation of combined therapy with chemoembolization and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol 1997;24(suppl 6):50-5.
121. Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197:812-8.
122. Elba S, Giannuzzi V, Misciagna G, et al. Randomized controlled trial of tamoxifen versus placeba in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994;26:66-8.
123. Farinati F, De Maria N, Fornasiero A, et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992;37:659-62.
124. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917-22.
125. Martinez Cerezo FJ, Tomas A, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-6.
126. Riestra S, Rodriguez M, Delgado M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998;26:200-3.
127. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-8.
128. Liu CL, Fan ST, Ng IO, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000;95:218-22.
129. Villa E, Dugani A, Fantoni E, et al Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996;56:3883-5.
130. Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000;12:281-4.
131. Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000;11:113-4.
132. Gebbia V, Maiello E, Serravezza G, et al. 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Anticancer Res 1999;19:1407-10.
133. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117-36.
134. Miyajima I, Sata M, Kumashiro R, et al. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment. Oncol Rep 1998;5:201-4.
135. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9.
136. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon- alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
137. Inoue A, Tsukuma H, Oshima A, et al. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. J Epidemiol 2000;10:234-40.
138. Kowdley KV. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? Gastroenterology 1999;117:738-9.
139. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-402.
140. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
141. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-7.
142. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatotogy 1993;17:389-94.
143. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8.
144. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
145. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long- acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91.